Viani (Seretide): German patent litigation update

Viani (Seretide): German patent litigation update

Issued: Thursday 20 May 2010, London UK, 10.00am BST

GlaxoSmithKline (GSK) today confirmed that the Federal Patents Court in Munich, Germany, has ruled in patent litigation regarding GSK's product Viani, an inhaled respiratory treatment for asthma and COPD. The Court ruled in favour of the claimants Mylan dura GmbH, Hexal AG, Neolab Ltd., and IVAX International B.V. in deciding that under German law GSK's German combination patent for Viani (relating to the combination of the active ingredients salmeterol and fluticasone propionate) was not valid.

The decision relates solely to the German combination patent for Viani and is not binding in any other jurisdiction. GSK also owns a number of other patents in Germany relevant to Viani including the Diskus dry powder inhaler and HFA aerosol formulation patents which expire in 2011 and 2012 respectively. In addition, there are significant technical hurdles and complexities associated with the introduction of inhaled respiratory products. GSK is studying the judgment and will be considering an appeal to a higher court.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com
 
GlaxoSmithKline Enquiries:
 
 
 
UK Media enquiries:
 Philip Thomson
 (020) 8047 5502
 
 
 Claire Brough
 (020) 8047 5502
 
 
 Stephen Rea
 (020) 8047 5502
 
 
 Alexandra Harrison
 (020) 8047 5502
 
 
 Jo Revill
 (020) 8047 5502
 
 
  
  
 
US Media enquiries:
 Nancy Pekarek
 (919) 483 2839
 
 
 Mary Anne Rhyne
 (919) 483 2839
 
 
 Kevin Colgan
 (919) 483 2839
 
 
 Sarah Alspach
 (919) 483 2839
 
 
 
 
 
European Analyst/Investor enquiries:
 David Mawdsley
 (020) 8047 5564
 
 
 Sally Ferguson
 (020) 8047 5543
 
 
 Gary Davies
 (020) 8047 5503
 
 
 
 
 
US Analyst/ Investor enquiries:
 Tom Curry
 (215) 751 5419
 
 
 Jen Hill Baxter
 (215) 751 7002
 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.